Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986020 in Idiopathic Pulmonary Fibrosis
NCT01766817Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of bms-986020 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change From Baseline in Forced Vital Capacity (FVC) Rate at 26 weeks. Started Jan 2013; status: completed.
02
Drugs
bms-986020
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01766817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766817.